In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.

Imperiale TF, ACP Journal Club Editorial Team at McMaster University

Open source

DOI
10.7326/annals-25-03308-jc
Published
2025 Sep
Container
Annals of internal medicine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7326/annals-25-03308-jc,
  title = {In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.},
  author = {Imperiale TF and ACP Journal Club Editorial Team at McMaster University},
  year = {2025},
  journal = {Annals of internal medicine},
  doi = {10.7326/annals-25-03308-jc},
  url = {https://doi.org/10.7326/annals-25-03308-jc}
}

RIS

TY  - JOUR
TI  - In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.
AU  - Imperiale TF
AU  - ACP Journal Club Editorial Team at McMaster University
PY  - 2025
JO  - Annals of internal medicine
DO  - 10.7326/annals-25-03308-jc
UR  - https://doi.org/10.7326/annals-25-03308-jc
ER  - 

APA

TF, I., & University, A. J. C. E. T. A. M. (2025). In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.. Annals of internal medicine. https://doi.org/10.7326/annals-25-03308-jc

Source records